Navigation Links
Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications
Date:9/30/2008

ISO certification confirms implementation of quality systems in product

design and development, manufacture, and distribution for Cylex's

ImmuKnow(R) immune cell function assay

COLUMBIA, Md., Oct. 1 /PRNewswire/ -- Cylex has announced receipt of certification to ISO 13485:2003 and 9001:2000. The 13485:2003 certification includes compliance with the Canadian Medical Devices Conformity Assessment System (CMDCAS). These certifications signify compliance with internationally recognized standards in design, development, and manufacturing of medical products. The certifications were issued by TUV Rheinland of North America.

"This is a major achievement for the Company," stated Brad L. Stewart, president of Cylex. "ISO certification confirms that quality systems have been implemented in product design and development, manufacture, operations, shipping, and service and will support CE marking of Cylex products that will be labeled for in vitro diagnostic use for sale within the European Community. In addition, the certification confirms that Cylex meets global quality design and manufacturing requirements for Canada."

ISO 13485:2003 provides Cylex's customers with a "Quality Pledge" in regard to the Company's ongoing dedication to quality manufacturing, as well as demonstrating our readiness to take on the demanding challenges of building medical devices that are robust and reliable.

"In addition to the ISO 13485:2003 certificate, Cylex voluntarily elected to obtain certification to ISO 9001:2000 as well," Stewart went on to say. "We did this to demonstrate our commitment to customer focus, customer satisfaction, and continuous quality improvement. And I want to take this opportunity to clearly recognize all Cylex's employees for the dedication, focus, and hard work that has made this certification possible."

Certification to ISO standards is a baseline quality system requirement in many key markets for approval to sell a medical device and therefore supports the Company's plans to market its ImmuKnow immune cell function assay to customers around the world.

About ImmuKnow(R)

ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.

About Cylex, Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products intended to illuminate immunity. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. Cylex has received certification to ISO 13485:2003 and 9001:2000 for its quality system for "design and development, manufacture and distribution of in vitro diagnostic products related to immune function testing". The Company is based in Columbia, MD USA.


'/>"/>
SOURCE Cylex
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):